erlotinib hydrochloride has been researched along with pteridines in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (pteridines) | Trials (pteridines) | Recent Studies (post-2010) (pteridines) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 2,792 | 46 | 628 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giri, U; Goonatilake, R; Heymach, JV; Johnson, FM; Li, L; Mino, B; Nilsson, M; Rodriguez-Canales, J; Singh, R; Tong, P; Villalobos, P; Wang, J; Wang, L; Wang, Y; Wistuba, I | 1 |
1 other study(ies) available for erlotinib hydrochloride and pteridines
| Article | Year |
|---|---|
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Xenograft Model Antitumor Assays | 2016 |